A recent clinical trial has demonstrated that a commonly used antibody treatment called hyperimmune intravenous immunoglobulin (hIVIG) therapy has no benefit in the management of Covid-19 patients.
Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Over the past 3 years, it has affected millions of people worldwide and has induced widespread panic and fear among the general public.
As the COVID-19 pandemic continues to impact people worldwide, researchers are working tirelessly to find effective treatments for those who are hospitalized with the virus. As a result, a new antibody treatment called IVIG was developed against this disease. The hope was that giving these antibodies to patients with COVID-19 would help their immune systems fight off the virus and improve their chances of recovery.
IVIG solution contains natural body proteins called antibodies which help fight off the Covid-19 virus inside the body. These antibodies are derived from the blood of people who have recovered from the Covid-19 disease.
A recent clinical study published in The Lancet journal has evaluated the effectiveness of antibody therapy called IVIG in the treatment of hospitalized patients suffering from Covid-19.
The clinical study involved 593 patients from 63 hospitals and 11 countries who were suffering from Covid-19. 301 patients were given IVIG while 292 patients were given alternative treatment. The patients were assessed 7 and 28 days later for Covid-19 symptoms which included respiratory symptoms, organ failure, and death.